Inhibition of soluble epoxide hydrolase (SEH), the enzyme responsible for degradation of vasoactive epoxides, protects against cerebral ischemia in rats. However, the molecular and biological mechanisms that confer protection in normotension and hypertension remain unclear. Here we show that 6 weeks of SEH inhibition via 2 mg/day of 12-(3-adamantan-1-ylureido) dodecanoic acid (AUDA) in spontaneously hypertensive stroke-prone (SHRSP) rats protects against cerebral ischemia induced by middle cerebral artery occlusion, reducing percent hemispheric infarct and neurodeficit score without decreasing blood pressure. This level of cerebral protection was similar to that of the angiotensin-converting enzyme inhibitor, enalapril, which significantly lowered blood pressure. SEH inhibition is also protective in normotensive WistarKyoto (WKY) rats, reducing both hemispheric infarct and neurodeficit score. In SHRSP rats, SEH inhibition reduced wall-to-lumen ratio and collagen deposition and increased cerebral microvessel density, although AUDA did not alter middle cerebral artery structure or microvessel density in WKY rats. An apoptosis mRNA expression microarray of brain tissues from AUDAtreated rats revealed that AUDA modulates gene expression of mediators involved in the regulation of apoptosis in neural tissues of both WKY and SHRSP rats. Hence, we conclude that chronic SEH inhibition protects against cerebral ischemia via vascular protection in SHRSP rats and neural protection in both the SHRSP and WKY rats, indicating that SEH inhibition has broad pharmacological potential for treating ischemic stroke. Epoxyeicosatrienoic acids (EETs), lipid metabolites produced from arachidonic acid by CYP450 enzymes, are novel mediators that antagonize the sequela of hypertension, 1 match cerebral blood flow to increased neural activity and metabolic demand, promotes angiogenesis, 2 and protect against ischemia.
Epoxyeicosatrienoic acids (EETs), lipid metabolites produced from arachidonic acid by CYP450 enzymes, are novel mediators that antagonize the sequela of hypertension, 1 match cerebral blood flow to increased neural activity and metabolic demand, promotes angiogenesis, 2 and protect against ischemia. 3, 4 Because ischemic stroke occurs with loss of cerebral blood flow and is strongly associated with hypertension, modulation of epoxide degradation has potential in managing ischemic stroke. Unfortunately, pharmacological utility of exogenous EETs is impractical because the epoxides are rapidly degraded by the soluble epoxide hydrolase (SEH) into their less active diol, dihydroxyeicosatrienoic acids. 5 In fact, human SEH polymorphisms are linked to the incidence of ischemic stroke, 6 and this association could be related to modifications in SEH activity, and thus epoxide catabolism. 7 An alternative strategy that has been used to increase EETs systemically is SEH inhibition. 1 We previously showed that the SEH inhibitor 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA) protects against cerebral ischemia in spontaneously hypertensive stroke-prone (SHRSP) rats, an animal model of essential hypertension. 8 Interestingly, chronic AUDA treatment in SHRSP rats effectively decreased infarct size induced by middle cerebral artery occlusion (MCAO) without decreasing blood pressure. 8 Although blood pressure is an important variable in controlling infarct size in the SHRSP, the cerebrovasculature is also a key determinant of increased sensitivity to cerebral ischemia and thus infarct size. 9, 10 Our study provided preliminary evidence that AUDA protection in the SHRSP involved changes in vascular structure. 8 More recently, a report suggested that administration of AUDA-butyl ester protects against cerebral ischemic reperfusion injury in normotensive mice by mechanisms that may involve neural protection rather than vascular protection. 11 As a result, the contribution of vascular and neural protection to the cerebral protective effects of SEH inhibition during states of hypertension and normotension are unclear and require further investigation. The present study tested the hypothesis that SEH inhibition provides cerebral protection via different mechanisms in normotensive WKY and hypertensive SHRSP rats.
Materials and Methods

Animals
All male animals were housed and fed a normal rat chow (Tekads 8604; Harlan, Indianapolis, IN) in the animal care facility at the Medical College of Georgia approved by the American Association for the Accreditation of Laboratory Animal Care and all protocols were approved by the institutional animal care and use committee at this institution. All drug treatments were administered via drinking water. Six-to seven-week-old SHRSP rats (Charles River, Wilmington, MA) were divided into four treatment groups as follows: 6 weeks of vehicle (500 mg/L of cyclodextrin and 0.075% of ethanol), 6 weeks of AUDA (2 mg/day via drinking water, 50 mg/L, dissolved using vehicle to aid in solubilization), 6 weeks of enalapril (2.5 mg/day via drinking water dissolved in vehicle), and 5 weeks of AUDA (2 mg/day via drinking water dissolved via vehicle followed by a 7-to 12-day washout period). In addition, a group of 12-to 13-week-old SHRSPs was treated with trans-4-͓4-(3-adamantan-1-yl-ureido)-cyclohexyloxy͔-benzoic acid (tAUCB), an SEH inhibitor, 12,13 2 mg/day for 7 to 12 days via drinking water (50 mg/L) prepared using vehicle to aid in solubulization. Six-to seven-week-old WKY (Harlan) were treated with either 6 weeks of vehicle or 6 weeks of AUDA, 2 mg/day. Blood pressure was monitored by tail plethysmography (IITC Life Science, Woodland Hills, CA) during the experimental period in acclimatized conscious rats. At the end of the treatment, all animals were anesthetized with pentobarbital (50 mg/kg) for middle cerebral artery occlusion (MCAO) experiments and tissue collection.
Plasma and Brain AUDA and Metabolite Measurements
AUDA levels were measured in homogenized brain, and AUDA metabolites were assessed in plasma samples by reverse phase high performance liquid chromatography followed by negative mode electron spray ionization and tandem mass spectroscopy as previously described.
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MCAO
MCAO was conducted as previously described by Longa and colleagues.
14 In brief, anesthetized rats with body temperature maintained at 37°C had a 3-0 dermalon monofilament with a rounded tip inserted cranially until a drop in the Laser Doppler (Perimed, North Royalton, OH) attached to the skull 2 mm down and 5 mm lateral to bregma confirmed MCA occlusion. 8 Physiological parameters (PO 2 , PCO 2 , hematocrit, and blood glucose) were measured via blood sampling with a femoral arterial line using a blood gas analyzer (GemPremier 3000; Instrumentation Laboratory, Lexington, MA). There were no differences in physiological parameters measured during the MCAO at baseline between vehicle and AUDA treatment (see Supplemental Table S1 at http://ajp. amjpathol.org).
Six hours after MCAO, neurodeficit was assessed using a combination of a modified form of the Bederson and colleagues 15 score and an abbreviated adaptation of the modified Neurological Severity Score described by Chen and colleagues. 16 The neurodeficit score for WKY animals consisted of a tail suspension test (score range, 1 to 4) to assess postural reflexes and a pad walk to assess motility (range, 1 to 3) that were combined for an overall neurodeficit score. SHRSP neurodeficit score also included an additional spontaneous activity score (1 to 4) to assess the more dramatic deficits displayed in the SHRSP rats, assessing general condition (calm to aggressive) and abnormal movements (curvilinear walk to seizure-like activity).
Next, brains were collected and sliced into 2-mm sections coronally from the frontal pole. Noninfarcted hemisphere, infarcted hemisphere, and infarct were measured using the National Institutes of Health (Bethesda, MD) Image software on digitized images of the slices stained with 2% triphenyltetrazolium chloride (TTC). Percent hemisphere infarct was calculated using the Swanson equation to account for swelling. 17 
Histology of MCA
Animals were perfused with a vasodilator cocktail (papaverine 0.3 mmol/L/L, adenosine 0.2 mmol/L, diltiazem 0.2 mmol/L/L) prepared in phosphate-buffered saline. A section of the MCA, 4 mm away from the Circle of Willis, was embedded. Serial sections of 5 m in thickness were taken equidistantly along 650 m, totaling 16 measurements per vessel. Outer and inner perimeters were measured via by a blinded reviewer using Axiovision 4.0 software (Axio Vision Rel.4.6.3; Carl Zeiss, Thornwood, NY). These measurements were used to calculate wall thickness and wall to lumen (W:L) ratio using the equation of a circle. The MCA was also stained for collagen with the Masson's trichrome stain and picrosirius red stain. The MCA was scored on a scale of 1 to 10 by two blinded observers.
Microvessel Density
Because the reduction in infarct size evident in SEH knockout mice was associated with increased perfusion in the cortex and striatum during MCA occlusion and early reperfusion 18 and we previously found that AUDA treatment reduced infarcted tissue in cortex and striatum, 8 we measured microvessel density in the cortex and the striatum of treated and control rats. To measure the microvessel density, the brains were collected and sliced into five 2-mm slices in the same manner used for TTC staining and infarct quantification. The slices are flashfrozen in a methylbutane dry-ice bath. 
Real-Time Polymerase Chain Reaction (PCR) Apoptosis Gene Expression Array
As previously described, 19 total RNA was extracted from 50 mg of whole brain from male rats using the RNeasy lipid mini kit and DNase digestion (Qiagen, Valencia, CA) according to the manufacturer's protocol and RNA concentrations were determined using absorbance at 260 nm. Using RT 2 PCR array first strand kit (SuperArray Bioscience, Frederick, MD), 1 g of RNA was converted to cDNA. The cDNA was then incubated with RT 2 real-time SYBR Green PCR mastermix (SuperArray Bioscience) into a 96-well PCR array plate, one sample per plate (three samples per experimental group). Thermal cycling and real-time detection via a Bio-Rad iCycler (Bio-Rad Laboratories, Hercules, CA) was conducted following the instructions of apoptosis array (Superarray Bioscience). The Superarray RT 2 PCR arrays are equipped with controls for genomic DNA contamination, reverse transcription, and PCR. Threshold cycle (C t ) values were normalized to ␤-actin. The significance analysis of microarrays (SAM) software (Stanford University, Stanford, CA) was used to determine the significance of changes in gene expression in the apoptosis microarray 20 with a median false discovery rate of 17% and q-value (comparable with P value) of 10%.
Statistics
All data are expressed as mean Ϯ SEM. Differences were assessed using analysis of variance and Student's t-tests with P values Ͻ0.05 being statistically significant.
Results
Brain AUDA and Plasma AUDA Metabolite Levels
AUDA is metabolized by ␤ oxidation into an inactive metabolite 12-(3-adamantyl-ureido)-butyl acid (AUBA). AUBA levels are used as an indication of AUDA exposure. Because AUDA reversibly and competitively inhibits the SEH enzyme, measuring SEH activity in the tissue to determine the degree of SEH inhibition is not feasible. 13, 21, 22 Plasma levels of AUBA reached 4 ng/ml in the SHRSP rats and 13 ng/ml in the WKY rats after 6 weeks of SEH inhibition. In the brain, AUDA levels reached 2 mol/g in the SHRSP rats and 3 mol/g in the WKY rats. These levels suggest that treatment was sufficient to inhibit SEH enzymatic activity.
AUDA Decreases Infarct Size Without Preventing Hypertension
AUDA treatment in the SHRSP rats did not prevent the development of hypertension in the 12-week-old SHRSP rats ( Figure 1 ) consistent with our previous findings. 8 To determine whether the protective effects of AUDA were independent of blood pressure lowering, additional SHRSP rats were treated with an angiotensin-converting enzyme inhibitor and served as a blood pressure control group for the SHRSP AUDA-treated rats. As expected, administration of the angiotensin-converting enzyme inhibitor enalapril (2.5 mg/day) for 6 weeks was effective at preventing the development of hypertension in the SHRSP rats. Despite the absence of an effect on blood pressure, the reduction in infarct size and neurodeficit achieved with AUDA was similar to that achieved by 6 weeks of enalapril treatment ( Figure 1 , A-D).
Previous studies have suggested that high concentrations of AUDA activate the orphan nuclear receptor PPAR-␣. 23, 24 Thus, we treated a separate set of SHRSP rats with tAUCB, a potent SEH inhibitor 12, 13 that lacks potential for PPAR agonistic activity ( Figure 1 ). As expected, tAUCB protected against cerebral ischemia in the SHRSPs, reducing infarct size to 43 Ϯ 3%, P Ͻ 0.05, hemispheric infarct size and neurodeficit score to 6.3 Ϯ 0.7, n ϭ 9, P Ͻ 0.05. These results indicate that the protective properties of AUDA are not attributable to PPAR agonistic activity but are the result of SEH inhibition.
Like the SHRSPs, AUDA treatment in the WKY did not alter blood pressure in the 12-week-old WKY rats (143 Ϯ 1 mmHg versus 141 Ϯ 3 mmHg). However, we still found a protective effect against cerebral ischemia in the WKY animals treated with AUDA. SEH inhibition significantly reduced percent infarct size 40% and neurodeficit 13% (Figure 2 , A-C).
AUDA Provides Vascular Protection in the SHRSP Rats
Previous studies have suggested that AUDA may mediate cerebral protection by increasing MCA compliance. 8 However, direct evidence implicating AUDA in vascular structure and remodeling is lacking. Thus, we analyzed blood vessel structure in the MCA in the SHRSP and WKY rats. The wall thickness and W:L ratio, two measures of vascular remodeling, and collagen deposition around the MCA were increased in the adult SHRSP in comparison with the adult WKY animals. Treatment with AUDA attenuated remodeling of MCA in SHRSP rats, manifest as a reduction in wall thickness (26%) and the W:L ratio (27%) (Figure 3, A and B ). In addition, there was an appreciable reduction in collagen deposition around the MCA of SHRSP AUDA-treated animals as determined by the Masson's trichrome stain and picrosirius red staining ( Figure 3 , C-J). Semiquantitative scoring by blinded reviewers determined that untreated SHR-SP had a collagen score of 7.8 Ϯ 0.3 and that this significantly decreased to 4.6 Ϯ 1.3 in AUDA-treated SHRSP. In contrast, we found that MCA wall thickness and W:L ratio of the WKY rats treated with AUDA was not altered ( Figure  3, A and B) . There was also no noticeable reduction in collagen deposition around the MCAs of AUDA-treated WKYs (Figure 3 , C-J).
To further investigate the impact of AUDA on the vasculature, we assessed cerebral microvessel density ͓area (mm 2 ) of fluorescence per area of field (mm 2 )͔. Assessment of immunofluorescently labeled von Willebrand factor in the brain parenchyma of SHRSP and WKY rats at the end of the treatment period revealed that the area of microvessel density in the adult SHRSP was 33% lower than the adult WKY rats (Figure 4, A, B, and D) . AUDA was again protective by increasing the microvessel density by 20% in the SHRSP rats (Figure 4 , A, D, and E). This supports the notion that SEH inhibition could be providing cerebral protection by reducing the area at risk to ischemia in the SHRSP rats. WKY rats did not exhibit any change in cerebral microvessel density in the WKY animals treated with AUDA ( Figure 4 , A-C).
To determine whether the protection achieved by chronic AUDA treatment could be sustained after discontinuation of treatment, a separate group of SHRSP rats were treated with AUDA, 2 mg/day, for 5 weeks followed by 7 to 12 days of AUDA withdrawal. The area under the curve (AUC) of orally administered AUDA is 0.4 ϫ 10 4 nmol/L . minute, 12 and the half-life for AUDA after oral gavage is 7.3 hours. 29 As a result, the withdrawal period should be sufficient to exclude the effects of the plasma presence of the drug AUDA. As anticipated, a trend for protection was still evident after the withdrawal period (46 Ϯ 9% hemispheric infarct, n ϭ 5, P Ͻ 0.26 and 7.6 Ϯ 0.8 neurodeficit, n ϭ 5, P Ͻ 0.20) further supporting the notion that chronic AUDA treatment protection from ischemic damage was in part attributable to structural changes in the SHRSP cerebrovasculature. 
Apoptosis
EETs and CYP overexpression reportedly antagonize intrinsic and extrinsic apoptosis. 30 -33 Also, EETs and SEH inhibition have been shown to promote cell survival during hypoxic reperfusion injury. 34 As a result, we undertook a global approach to assess expression of apoptotic genes (see Supplemental Table S2 at http://ajp. amjpathol.org for gene description of the 84 genes analyzed in the PCR plate) in brain samples collected from controls and AUDA-treated SHRSP and WKY rats using an apoptosis PCR microarray ( Figure 5 and Table 1 ). We have identified 57 genes up-regulated Ն1.5-fold and 25 Ն2-fold in the SHRSP in comparison with the WKY encoding tumor necrosis factor (TNF) ligands and receptors, members of the Bcl-2 family, caspases, nuclear factor (NF)-B1, and factors involved in DNA damage-induced apoptosis (Table 1 and Figure 5 , A and E). In contrast, AUDA-treated SHRSP had only 1 gene up-regulated Ն2-fold and 11 Ն1.5-fold in comparison with WKY ( Figure 5 , C and E; and Table 1 ). Furthermore, AUDA reduced gene expression of 39 apoptotic factors Ն1.5-fold and 32 Ն2-fold versus SHRSP vehicle-treated rats ( Figure 5, B 43 and an antioxidant peroxiredoxin 2 (Prdx2) in the WKY animals (Table 1 and Figure 5E ).
Discussion
In this study, we investigated vascular and nonvascular mechanisms by which AUDA can protect against cerebral ischemia in normotension and hypertension. Although chronic SEH inhibition via AUDA protects SHRSP rats via vascular and neural protection, only neural protection was observed in WKY rats. Chronic AUDA treatment of SHRSP rats protected through vascular protection by attenuating the hypertrophic remodeling and collagen deposition that occurs in the large cerebral vessel of the SHRSP rats.
9,10 Several reports suggest that EETs and SEH inhibition may attenuate vascular remodeling by modulating intracellular signaling pathways in vascular smooth muscle cells 44 and fibroblasts. 45 Our laboratory has previously shown that SEH inhibition with 1-cyclohexyl-3-dodecyl-urea (CDU) decreased collagen deposition in kidneys of angiotensininfused hypertensive rats and decreased renal vascular remodeling.
1 Furthermore, we have previously found increased MCA compliance in SHRSP rats chronically treated with AUDA. 8 This corroborates our current findings of reduced W:L ratio, wall thickness, and collagen deposition in the SHRSP.
In addition to its effects on the MCA, AUDA treatment increased cerebral microvessel density in the SHRSP rats. Jesmin and colleagues 27, 28 reported that SHRSP rats have reduced regional cerebral blood flow, angiogenic factors, and cerebral microvessel density in the cerebral cortex at 6 weeks of age in comparison with age-matched WKY rats. 28 In our study, vehicle-treated SHRSP rats also demonstrated reduced cerebral microvessel density at 12 weeks of age, the time of occlusion, in comparison with the WKY rats to a degree similar to the previous report. EETs have been shown to induce angiogenesis in several in vivo models and on co-culture of astrocytes and endothelial cells. 2 Because hypoxia and increased metabolic demand are potential triggers for astrocyte EET-mediated angiogenesis, 46 we speculate that SEH inhibition resulted in increased cerebral microvessel density by countering the deficiencies present in the SHRSP rats. Interestingly, there was a trend for maintenance of the cerebral protection in SHRSP rats after AUDA was withdrawn for 7 to 12 days. Taken together, these results suggest that cerebral protective effects of AUDA in SHRSP rats were in part attributable to structural changes in the vasculature. Unlike the effects of AUDA on vascular remodeling and microvessel density, SEH inhibition provided neural protection in both normotensive and hypertensive rat strains by modulating gene expression of mediators involved in the regulation of apoptosis in the brain tissue of both WKY and SHRSP rats. We propose that the up-regulation of the anti-apoptotic mediators and neuroprotectants in the WKY and dampening of overexpression of pro-apoptotic mediators in the SHRSP rats may set the stage for increased tolerance of cellular stress. Although the studies conducted here were on tissue pre-ischemic insult and therefore do not allow for the determination of the specific genes that may be involved in providing protection from cerebral ischemia, they do show that SEH inhibition causes a global change in the expression of mediators involved in the apoptotic pathway. The range of fold changes in expression levels we detected are in accordance with prior reports 31 of apoptotic gene expression and protein expression pre-insult, which report smaller inductions pre-insult that prime the cells for a dramatic up-regulation on induction of apoptosis, and thus promotion of cell survival. 31 However, because of the limitations of our study, we cannot determine the cell type or specific genes that could be attributed to possible neuroprotection. The SAM statistical analysis is limited by the occurrence of false-positives, and we have not confirmed changes in gene expression by cellular localization, subcellular localization, or protein analysis.
The changes that we report with SEH inhibition do however corroborate previous findings of the anti-apoptotic properties of EETs, CYP overexpression, and SEH inhibition. EETs and CYPs reportedly inhibit apoptosis induced by Fas ligand, 30 TNF-␣ induced, 31,32 serum deprivation, 30 etoposide, arachidonic acid, ceramide production, inhibition of reactive oxygen species, 33 and hypoxic reperfusion possibly by antagonizing reactive oxygen species. 34 Our data are also in agreement with a previous report that MAPK and PI3/Akt signaling pathways protect endothelial cells from TNF-␣ induced apoptosis. 31 Closely related, a recent study linked human SEH polymorphisms to cortical neuronal sensitivity to oxygen-glucose deprivation. Overexpression of SEH and human polymorphisms associated with variations in SEH activity increased cell death induced by oxygen-glucose deprivation. 47 To the best of our knowledge, our study is the first to provide a possible link to the neuroprotection achieved via SEH inhibition with AUDA in hypertension and normotension with a shift in the balance in the gene expression of pro-and anti-apoptotic mediators, producing possible ischemic tolerance.
Previous reports indicate that AUDA has PPAR-␣ activity at high concentrations most probably attributable to its long alkyl chain. 23, 24 Its structural similarity to fatty acids makes the compound lipophilic, which increases its ability to bind to the hydrophobic ligand-binding domain of PPAR-␣. 23, 24 Although we cannot exclude the possibility of PPAR-␣, the AUBA levels achieved in the present study were in the nanomolar range, which would indicate that AUDA levels were not sufficient to induce PPAR-␣ activity. We also found protection with a nonalkanoic acid SEH inhibitor, tAUCB. Not only does tAUCB lack the long fatty acid chain required for PPAR-␣ binding, tAUCB is more polar than AUDA. 12, 13 As a result, tAUCB lacks potential for binding to the hydrophobic PPAR-␣ binding domain. 48, 49 Moreover, mice that had the gene responsible for SEH production deleted also were protected from cerebral ischemic reperfusion injury. 50 Based on our current findings and published findings in the Ephx2 Ϫ/Ϫ mice, we conclude that the protection from cerebral ischemia with AUDA treatment is most likely to be attributable to SEH inhibition.
In our study, the SHRSP and WKY animals were treated with AUDA in the drinking water, as in our prior study. 8 In our prior study, the AUDA and AUBA plasma levels were sufficient to show adequate inhibition of the SEH enzyme as demonstrated by an increase in the urinary epoxide to diol ratio. In the current study, we do not have confirmatory data to show the level of SEH inhibition via the epoxide to diol ratio in the brain or plasma. However, the plasma and brain AUDA metabolite and AUDA drug levels are similar to that previously established as therapeutic in our prior study. 8 In addition, measuring the degree of SEH inhibition directly is more difficult because AUDA reversibly and competitively inhibits the SEH enzyme. 13, 21, 22 In the current study, the AUDA plasma levels were variable between the WKY and SHRSP animals, and could be attributable to differences in the drinking water intake between the strains. We cannot rule out possible differences in pharmacokinetics and AUDA metabolism between the rat strains. However, the brain tissue levels of AUDA were very similar between the two groups in our study. The reason for similar brain AUDA levels is not known but could be related to the blood brain barrier or to brain compartmentalization of AUDA. We did not measure brain AUDA levels in the prior study. As a result, we cannot determine relative differences in between dose and brain tissue levels of AUDA in this study in comparison with our prior study. Yet, the doses of the SEH inhibitor were similar to those also shown to be protective against LPS challenge in mice. ically relevant. Conducting these studies in an animal model with hypertension is essential for addressing the main patient population affected by ischemic stroke. 51 Based on the TOAST study subclassifications, 36 to 56.6% of ischemic strokes are reportedly related to vascular disease associated with hypertension, such as large vessel atherosclerosis and small artery disease. 52, 53 Moreover, human SEH polymorphisms have been found to alter SEH activity 7 and not only affect the incidence of ischemic stroke but also hypertension and atherosclerosis. 1, 6 Smoking, another risk factor for ischemic stroke, synergistically increases the prevalence of hypertension and atherosclerotic disease with the SEH polymorphisms. 1 Because SEH polymorphisms are linked to both ischemic stroke and its modifiable risk factors, modulating SEH enzymatic activity may be beneficial in decreasing the incidence and severity of ischemic stroke in high-risk patients. It is also important to address the nonhypertensive population and the patients without evidence of vascular disease that have cerebral ischemic events. The ability of SEH inhibition to protect in the absence of hypertension and vascular disease implicates that SEH inhibition may also be beneficial in treating the nontraditional ischemic stroke patients. This hypothesis is further confirmed by the epidemiological association of increased risk for ischemic stroke with Ephx2 gene polymorphisms in patients with large artery disease and patients lacking the traditional etiology for ischemic stroke. 54 In summary, we show that chronic SEH inhibition is protective during cerebral ischemia in hypertensive and nonhypertensive rats. SEH inhibition normalized cerebrovascular structure in hypertensive animals and provided neural protection in normotensive and hypertensive rats. Overall, the ability of AUDA to provide protection in the presence or absence of hypertension is clinically relevant because ischemic stroke occurs in hypertensive and nonhypertensive patients. The TOAST subclassifications demonstrates the heterogeneity of the ischemic stroke patient population, 52, 53 and as a result, using a treatment that can act through multiple mechanisms of protection under varying clinical presentations further increases the patient population that can be effectively treated. As a result, SEH inhibition has broad pharmacological potential for ischemic stroke management, and its utility should be further investigated.
